Skip to main content
. 2022 Jul 18;122(10):1683–1692. doi: 10.1055/s-0042-1749438

Table 1. Characteristics of patients and control subjects.

Controls ( n  = 23) COVID-19 ( n  = 25) p -Value
Demographics
 Age (y) 53.3 (18.8) 60.8 (13.0) 0.12
 Gender (male), n (%) 11 (47.8) 12 (48.0) >0.99
 BMI 27.0 (7.5) 29.7 (4.8) 0.16
Medical history
 Hypertension (medicated), n (%) 8 (34.8) 9 (36.0) >0.99
 Prior stroke, n (%) 2 (8.7) 1 (4.0) 0.60
 Diabetes mellitus, type 2, n (%) 5 (21.7) 5 (20.0) >0.99
 Atherosclerosis, n (%) 1 (4.3) 1 (4.0) >0.99
 Chronic kidney disease, n (%) 0 (0.0) 2 (8.0) 0.49
 Prior malignancy, n (%) 4 (17.4) 1 (4.0) 0.18
Chronic medication
 Platelet aggregation inhibitors, n (%) 3 (13.0) a 2 (8.0) b 0.66
 Statins, n (%) 5 (21.7) 4 (16.0) 0.49
Disease course
 qSOFA c (on admission) 1 [0.0, 1.0]
 MEWS d (on admission) 3 [2.0, 5.0]
 PSI e (on admission) 2 [1.0, 5.0]
 Mortality (day 28), n (%) 4 (16.0)
 Hospital length of stay (days) 6.2 (7.8)
 ICU admission, n (%) 2 (8.0)
Laboratory tests f
 C-reactive protein (mg/L) 111.42 (69.13)
 Platelets (× 10 9 /L) 290 (166) 274 (108) 0.79
 Leukocytes (×10 9 /L) 5.8 [3.6–16.3] 6.9 [3.3–25.9] 0.22
 Neutrophils (×10 9 /L) 3.8 [1.5–10.2] 5.0 [1.5–21.2] 0.04
 Lymphocytes (×10 9 /L) 1.2 [0.8–3.4] 0.9 [0.2–3.3] 0.08

Note: Continuous data are presented as mean (standard deviation) or median [range], and compared using a two-sided one-way analysis of variance (equal variances not assumed) or two-sided Kruskal–Wallis test, respectively. Categorical data are presented as counts and compared using Fisher's exact test.

a

Aspirin ( n  = 1), clopidogrel ( n  = 1), aspirin + clopidogrel ( n  = 1).

b

Aspirin ( n  = 2).

c

qSOFA = quick sequential organ failure assessment score.

d

MEWS = modified early warning score.

e

PSI = pneumonia severity index.

f

Measured upon presentation to the emergency department (for patients).